Literature DB >> 2158940

Prognostic factors for malignant mixed müllerian tumors of the uterus.

W Schweizer1, R Demopoulos, U Beller, N Dubin.   

Abstract

This study examined factors affecting the survival of 28 consecutive patients with malignant mixed Mullerian tumors diagnosed at New York University Medical Center from 1971 through 1985. The cumulative 5-year survival for all patients was 38%. Patients with pedunculated tumors (18/25) had a significantly improved 5-year survival of 53% compared with patients having a tumor with a broad-based attachment (7/25), all of whom died within 1 year (p less than 0.01). Eleven patients whose tumors demonstrated vascular invasion had a worse prognosis compared with 14 patients without demonstrable vascular invasion (18% versus 53% 5-year survival; p less than 0.05). Interestingly, patients with pedunculated tumors persisted in having an improved survival even after correcting for vascular invasion, compared with patients having broad-based tumor attachment. Small tumor size (less than or equal to 7 cm) also proved to be a significant and independent prognostic indicator for improved survival. Advanced stage, heterologous sarcomatous elements, and deep myometrial invasion (greater than one-third invasion) tended to be associated with decreased survival, but not with statistical significance. Patient age and grade of the carcinoma element did not appear to affect survival.

Entities:  

Mesh:

Year:  1990        PMID: 2158940     DOI: 10.1097/00004347-199004000-00004

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  6 in total

1.  Comparison of survival outcomes between patients with malignant mixed mullerian tumors and high-grade endometrioid, clear cell, and papillary serous endometrial cancers.

Authors:  Ashley Sinclair Felix; Roslyn A Stone; Robert Bowser; Mamatha Chivukula; Robert P Edwards; Joel L Weissfeld; Faina Linkov
Journal:  Int J Gynecol Cancer       Date:  2011-07       Impact factor: 3.437

2.  DNA Mismatch Repair-deficient Endometrial Carcinosarcomas Portend Distinct Clinical, Morphologic, and Molecular Features Compared With Traditional Carcinosarcomas.

Authors:  Sheila E Segura; Silvana Pedra Nobre; Yaser R Hussein; Nadeem R Abu-Rustum; Britta Weigelt; Robert A Soslow; Deborah F DeLair
Journal:  Am J Surg Pathol       Date:  2020-11       Impact factor: 6.394

3.  Uterine carcinosarcomas: 8-year single center experience of 25 cases.

Authors:  Kalpana S Dave; Anjana Chauhan; Ronak Bhansali; Ruchi Arora; Sushma Purohit
Journal:  Indian J Med Paediatr Oncol       Date:  2011-07

4.  Adjuvant treatment modalities, prognostic predictors and outcomes of uterine carcinosarcomas.

Authors:  Kemal Gungorduk; Aykut Ozdemir; Ibrahim E Ertas; Mehmet Gokcu; Elcin Telli; Tufan Oge; Ahmet Sahbaz; Sevil Sayhan; Muzaffer Sanci; Mehmet Harma; Sinan Ozalp
Journal:  Cancer Res Treat       Date:  2014-09-04       Impact factor: 4.679

5.  Gonadotrophin-releasing hormone (GnRH) analogues in the treatment of mixed mullerian tumours of the uterus: two case reports and review.

Authors:  M Katesmark; F Lawton
Journal:  Sarcoma       Date:  1998

6.  Outcomes of carcinosarcoma in a tertiary care institution in India.

Authors:  Anne George Cherian; Anitha Thomas; Ajit Sebastian; Tunny Sebastian; Vinotha Thomas; Rachel G Chandy; Abraham Peedicayil
Journal:  South Asian J Cancer       Date:  2018 Jan-Mar
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.